Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy; Department of Urology, Onze-Lieve-Vrouwziekenhuis, Aalst, Belgium; ORSI Academy, Melle, Belgium.
Department of Urology, Onze-Lieve-Vrouwziekenhuis, Aalst, Belgium; ORSI Academy, Melle, Belgium; Department of Urology, University of Bologna, Bologna, Italy.
Urol Oncol. 2022 Feb;40(2):65.e1-65.e9. doi: 10.1016/j.urolonc.2021.09.021. Epub 2021 Nov 22.
International guidelines suggest the use of anatomic scores to predict surgical outcomes after partial nephrectomy (PN). We aimed at validating the use of Simplified PADUA Renal (SPARE) nephrometry score in robot-assisted PN (RAPN).
Three hundred and sixty-eight consecutive RAPN patients were included. Primary endpoints were overall complications, postoperative acute kidney injury (AKI) and TRIFECTA achievement. Secondary endpoint was estimated glomerular filtration rate (eGFR) decrease at last follow-up. Multivariable logistic and linear regression models were used.
Of 368 patients, 229 (62%) vs. 116 (31%) vs. 23 (6.2%) harboured low- vs. intermediate- vs. high-risk renal mass, according to SPARE classification. SPARE score predicted higher risk of overall complications (Odds ratio [OR]: 1.23, 95%CI 1.09-1.39; P < 0.001), and postoperative AKI (OR: 1.20, 95%CI 1.08-1.35; P < 0.01). Moreover, SPARE score was associated with lower TRIFECTA achievement (OR: 0.89, 95%CI 0.81-0.98; P = 0.02). Predicted accuracy was 0.643, 0.614 and 0.613, respectively. After a median follow-up of 40 (IQR: 21-66) months, eGFR decrease ranged from -7% in low-risk to -17% in high-risk SPARE.
SPARE scoring system predicts surgical success in RAPN patients. Moreover, SPARE score is associated with eGFR decrease at long-term follow-up. Thus, the adoption of SPARE score to objectively assess tumor complexity prior to RAPN may be preferable.
国际指南建议使用解剖评分来预测部分肾切除术(PN)后的手术结果。我们旨在验证简化的 PADUA 肾脏(SPARE)肾切除术评分在机器人辅助 PN(RAPN)中的应用。
共纳入 368 例连续 RAPN 患者。主要终点是总体并发症、术后急性肾损伤(AKI)和 TRIFECTA 达标。次要终点是最后随访时估计肾小球滤过率(eGFR)的下降。采用多变量逻辑和线性回归模型。
根据 SPARE 分类,368 例患者中,229 例(62%)、116 例(31%)和 23 例(6.2%)分别为低危、中危和高危肾脏肿块。SPARE 评分预测总体并发症风险更高(优势比[OR]:1.23,95%置信区间 1.09-1.39;P<0.001)和术后 AKI(OR:1.20,95%置信区间 1.08-1.35;P<0.01)。此外,SPARE 评分与 TRIFECTA 达标率较低相关(OR:0.89,95%置信区间 0.81-0.98;P=0.02)。预测准确率分别为 0.643、0.614 和 0.613。中位随访 40(IQR:21-66)个月后,eGFR 下降范围从低危 SPARE 的-7%到高危 SPARE 的-17%。
SPARE 评分系统预测 RAPN 患者手术成功。此外,SPARE 评分与长期随访时的 eGFR 下降相关。因此,在 RAPN 前采用 SPARE 评分客观评估肿瘤复杂性可能更优。